Ticker LaunchIPO · NXTC
NextCure, Inc.
NextCure, Inc. (NXTC) priced its initial public offering on May 9, 2019 at $15.00 per share, raising $75M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $329M. Hogan Lovells advised the company and Cooley advised the underwriters.
NextCure, Inc. is a clinical-stage biopharmaceutical company discovering immunomedicines for cancer and other immune-related diseases by restoring normal immune function. Its FIND-IO platform studies immune cells to identify targets, focusing on patients who do not respond to current therapies.
- Status
- IPO
- Ticker
- NXTC
- Exchange
- Nasdaq Global Select
- Priced
- May 9, 2019
- IPO price
- $15.00
- Raised
- $75M
- Market cap at IPO price
- $329M
- First filed
- Apr 12, 2019
- Company counsel
- Hogan Lovells
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- MD
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 12, 2019
- Latest amendment May 8, 2019
- Final prospectus (424B4) May 9, 2019
- All filings on EDGAR CIK 1661059
Other Biotech & pharma IPOs in 2019
- Bicycle Therapeutics PLCBCYC · May 23, 2019 · $60.7M
- Applied Therapeutics, Inc.APLT · May 14, 2019 · $40M
- Axcella Health Inc.AXLA · May 9, 2019 · $71.4M
- IRulya Therapeutics Inc.CRTX · May 9, 2019 · $75M
- Milestone Pharmaceuticals Inc.MIST · May 9, 2019 · $82.5M
- Trevi Therapeutics, Inc.TRVI · May 8, 2019 · $55M